Imatinib in the treatment of solid tumours

Abstract

The extraordinary success of imatinib in gastrointestinal stromal tumors (GIST) represents a model for molecularly targeted therapy for other solid tumors. Research is currently going to identify the molecular basis of mechanisms of action and drug resistance. In this article, we review recent advances in the clinical management of patients with GISTs treated with imatinib, but also of patients with dermatofibrosarcoma protuberans, chordoma, aggressive fibromatosis, and some other common solid tumors treated with this drug. We reviewed the knowledge of the molecular mechanisms that are basic to imatinib effects in these tumors.

Immunoreactivity of c-kit Receptor Protein during the Prehibernation Period in the Oviduct of the Chinese Brown Frog, Rana chensinensis

“…The present study was the first demonstration of the expression of the c-kit receptor in the oviduct of vertebrates besides humans. Aberrant ligand-independent activation of the c-kit receptor has been implicated in the development and progression of tumors, in particular those of stroma origin [10,17]. Although we do not understand the importance of the c-kit receptor in reproduction of R. chensinensis, the results of this study showed that the c-kit receptor was present in oviduct tissues expanded during the prehibernation period.…”

Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials

“…These disappointing results suggest that the overexpressed c‐KIT receptors are not actively signaling in ACC cells or are not the major drivers of the malignant phenotype. Additionally, it is now clear from sequencing data that ACC tumors express wild‐type c‐KIT 24, 25, 66, 68, 69…”

Adaptation of a human gut epithelial model in relation to the assessment of clinical pharmacokinetic parameters for selected tyrosine kinase inhibitors

“…This loosely related family of molecules specifically target the tyrosine kinase domain of growth factor receptors in the cellular membrane or cytosol which play an important role in the control of cell growth and replication [1][2][3][4]. Two of the most commonly used TKIs are erlotinib (non-small cell lung cancer (NSCLC), pancreatic cancer (PC)) and gefitinib (NSCLC) [5].…”